David Hallal, CEO at ALEXION PHARMACEUTICALS INC (ALXN), sold 11,297 shares at $143.81 ($1.6M) on 2016-02-04, disclosed to the SEC on 2016-02-08.
Seasonal sale ($1.6M) by CEO — this insider has traded ALXN in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $143.81 | 619 | $89K | 5.6% |
| 2 | $145.05 | 10 | $1K | 0.1% |
| 3 | $140.49 | 1,490 | $209K | 13.2% |
| 4 | $141.40 | 3,710 | $525K | 33.0% |
| 5 | $142.35 | 712 | $101K | 6.4% |
| 6 | $143.45 | 300 |
| $43K |
| 2.7% |
| 7 | $144.45 | 400 | $58K | 3.6% |
| 8 | $145.01 | 110 | $16K | 1.0% |
| 9 | $138.02 | 337 | $47K | 2.9% |
| 10 | $138.02 | 3,492 | $482K | 30.4% |
| 11 | $139.18 | 117 | $16K | 1.0% |
| Total | $140.50 avg | 11,297 | $1.6M | 100% |
| Filing → |
| ITOS | SELL | 2025-06-06 | $2.3M | — | Filing → |
| ALVR | SELL | 2022-10-21 | $5.1M | — | Filing → |
| ALVR | SELL | 2022-09-30 | $2.9M | — | Filing → |